Sage Journals: Discover world-class research

Abstract

Introduction

Human papillomavirus (HPV) infection is a common sexually transmitted infection often associated with cancer development. This study aimed to estimate the prevalence of HPV in women receiving care at the AUNA healthcare network in Peru.

Methods

We conducted an observational, descriptive, cross-sectional, retrospective study. A de-identified database of HPV-positive women who underwent the BD Onclarity™ HPV Assay between December 2018 and December 2021 at Auna clinics was analyzed. The database contained information regarding age, city, and HPV type. High-risk HPV types were analyzed individually (16, 18, 31, 45, 51, 52) and pooled [P1 (33, 58), P2 (56,59,66), and P3 (35,39,68)]. The study was approved by an independent research ethics committee in Peru.

Results

Of 68,714 women included in the study, the HPV prevalence was 14.21% (N = 9765, 95%CI:13.95%–14.47%). The highest prevalence was detected in Piura (16.85%, 95%CI:15.40%–18.38%), where HPV-51, HPV-52, HPV-P1, HPV-P2, and HPV-P3 were most common compared to other Peruvian cities included in the study. In Arequipa, the prevalence was the lowest (13.58%, 95%CI:12.38%–14.85%), but the percentage prevalence of HPV-16 was the highest compared to other cities. The prevalence of multiple HPV infections was 2.88% (N = 1981, 95%CI:2.76%–3.01%), with most of them co-presenting two types of HPV (N = 1522). The most frequent co-occurrences were P2 and P3, P2 and 52, and P2 and 16. Among HPV-positive women, the mean age was 41.31 years (±9.48) and 25.29% were in the 31–35 years group. HPV-P2 was the most frequent in all age groups except in the 65–72 years group, where HPV-P3 was the most common.

Conclusion

HPV prevalence was shown to be highest in Piura, with the most prevalent types being HPV-16, HPV-52, and HPV-P2 (HPV-56, -59, -66). HPV infection was found to be more frequent among women in the 31–35 years age group.

Keywords

HPV human papillomavirus HPV infections cervical cancer epidemiology

Background

Human papillomavirus (HPV) is one of the most common sexually transmitted infections worldwide.¹ In fact, most sexually active individuals are likely to acquire HPV at some point in their lives,² usually without any symptoms and with infections resolving on their own without treatment.³ However, persistent infections can lead to different health issues.⁴

HPV encloses over 200 types of viral strains, but only some of them have oncogenic potential.¹ This high-risk HPV group includes strains 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. Although HPV has been mostly associated with cervical cancer, it is also strongly linked with anal, vaginal, vulvar, penile, and oropharyngeal cancers.⁵ Furthermore, between 4.5%–5.2% of all cancers diagnosed worldwide could be attributed to HPV infections.^5-8

Even though HPV vaccination has been proven as an effective method to prevent cancers associated with this viral infection,⁶ cervical cancer is still the fourth most common cancer among women worldwide, being most prevalent and fatal in low- and middle-income countries. In Peru, the age-standardized incidence and mortality rates are 23.9 and 12.1 per 100.000, respectively. In 2022, 4809 Peruvian women were diagnosed and 2545 died from cervical cancer, becoming the second most common neoplasia, among women, and the leading cause of death.⁹ Remarkably, HPV has been found in 99.7% of cervical cancers.¹⁰

The prevalence of HPV varies depending on the geographical region, development index, ethnicity, lifestyle, sex, and age, among other factors.^11-14 For instance, the highest prevalence has been reported in Sub-Saharan Africa (24.0%), followed by Eastern Europe (21.4%), and Latin America (16.1%).¹⁴ Similarly, in Peru, the HPV prevalence differs significantly within the country, ranging from 8.4% to 43.9%,^15-18 depending on geographical site, HPV type, method of detection and age.

AUNA is a private healthcare network with hospitals and ambulatory medical centers in different cities in Peru, Colombia and Mexico. In Peru, Auna has a presence in Lima, Arequipa, Trujillo, Chiclayo and Piura, all five of these among the seven most populated cities in the country. In addition, Lima is the capital city of Peru, while Piura, Chiclayo and Trujillo are located in the northern region and Arequipa is located in the south of Peru.

In order to develop and implement more effective health policies to reduce the burden of HPV infections and cervical cancer, analysis of the HPV prevalence is imperative. Thus, we conducted a study aimed at estimating the prevalence of high-risk HPV strains within the AUNA network, segregating the results by HPV type, age group and concomitant infections.

Methods

Study Design and Population

We conducted an observational, descriptive, cross-sectional, retrospective study, by analysis of a de-identified database of HPV-positive women who underwent molecular HPV testing at AUNA hospitals located in five geographical regions, Piura (Piura), Lambayeque (Chiclayo), La Libertad (Trujillo), Lima (Lima) and Arequipa (Arequipa), from December 2018 to December 2021. The de-identified data was obtained from the pathology department record system and included age, location, and HPV-type. Patients under 16 years with cervical lesions were included. In cases where more than one diagnostic test was done during the study period, only the first result was included.

The reporting of this study aligns with the STROBE guidelines.¹⁹

HPV Testing

Cervical samples were collected using a cytobrush and sent to the central laboratory of Auna in Lima. HPV genotyping was done using the BD Onclarity™ HPV Assay. This qualitative assay employs real-time PCR and fluorescent probe technology to identify the E6 and E7 DNA regions of the HPV genome. Results are reported as either presence or absence of high-risk HPV, individually for the following types: 16, 18, 31, 45, 51 and 52, or pooled: P1 (33, 58), P2 (56,59,66), and P3 (35,39,68). A cellular β-globin control is included to differentiate HPV-negative samples from those that do not present an HPV signal due to insufficient cell mass in the sample. Testing was conducted using the BD Viper™ LT system following the manufacturer’s instructions.

Statistical Analysis

A descriptive analysis of the collected information was performed, and absolute frequencies and percentages were estimated. To calculate the HPV prevalence, the pathology department provided the total number of women tested within the study period in each clinic. The 95% confidence intervals for HPV prevalence were calculated using the Clopper–Pearson interval method. The analysis and plots were performed with the R Studio Software (2023.12.1- 402 version; RStudio PBC, Boston, MA, USA).

Ethical Considerations

This study was approved by the Ethics Research Committee of the Universidad Privada San Juan Bautista (N°1142-2024-CIEI-UPSJB) located in Lima, Peru, in July of 2024.

Results

HPV Prevalence

A total of 68,714 women, who underwent molecular HPV testing, were evaluated during the study period. Most of them were located in Lima (N = 56,628, 82.4%), followed by La Libertad (N = 3699, 5.4%), Arequipa (N = 3042, 4.4%), Lambayeque (N = 2859, 4.2%) and Piura (N = 2486, 3.6%). HPV global prevalence was 14.21% (N = 9765, 95% CI: 13.95% – 14.47%). The highest prevalence was identified in Piura, where 16.85% were positive (N = 419, 95%CI: 15.40%–18.38%), while the lowest prevalence was 13.58%, in Arequipa (N = 413, 95%CI: 12.38% – 14.85%) (Figure 1).

Figure 1.

HPV prevalence by department in which AUNA clinics are located. The figure shows the prevalence of HPV and HPV type, according to the geographical distribution of the molecular HPV testing by departments. N: Number of HPV positive women. %: Prevalence. 95% CI: 95% confidence interval.

The most prevalent HPV types were HPV-P2 (56,59, 66) (3.79%, 95%CI: 3.65% - 3.93%), HPV-16 (2.83%, 95%CI: 2.70% – 2.95%) and HPV-52 (2.27%, 95%CI: 2.16% – 2.38%) (Figure 2). Furthermore, 2.88% of women were positive for more than one HPV type (N = 1981, 95%CI: 2.76%–3.01%).

Figure 2.

Prevalence of HPV types. The figure shows the prevalence of each HPV type, in the evaluated population. N: Number of HPV positive women. %: Prevalence. 95% CI: 95% confidence interval.

Regarding the prevalence of HPV types by geographic region where AUNA hospitals are located, HPV-16 was remarkably predominant in Arequipa (3.55%, 95%CI: 2.92 – 4.27), followed by HPV-31 (2.30%, 95%CI: 1.8 – 2.9). On the other hand, HPV- positive women tested in Piura showed a higher prevalence of HPV-51, HPV-52, HPV-P1, HPV-P2 and HPV-P3 compared to other regions (Figure 1).

HPV Type Distribution in HPV- Positive Women

Within the group of HPV-positive tests (N = 9765), the most frequent type corresponded to P2 (56,59, 66) (26.7%), followed by 16 (19.9%) and P3 (35,39, 68) (18.7%). The least frequent type was 18 (4.3%) (Table 1). Excluding pooled detection, the most frequent types were 16 (31.99%), 52 (22.94%), and 31 (20.29%).

Table 1.

Distribution of the Frequency of HPV Among Positive Women According to Type and Age Group.

Age Group	HPV Type	16	18	31	45	51	52	P1	P2	P3
Age Group	N (%) 9765 (100.0%)	N (%) 1943 (19.9)	N (%) 421 (4.31)	N (%) 1346 (13.78)	N (%) 612 (6.27)	N (%) 755 (7.73)	N (%) 1557 (15.94)	N (%) 1264 (12.94)	N (%) 2602 (26.65)	N (%) 1829 (18.73)
16-20	27 (0.28)	9 (33.33)	2 (7.41)	5 (18.52)	2 (7.41)	3 (11.11)	6 (22.22)	3 (11.11)	13 (48.15)	5 (18.52)
21-25	119 (1.22)	21 (17.65)	8 (6.72)	14 (11.76)	13 (10.92)	15 (12.61)	29 (24.37)	16 (13.45)	55 (46.22)	28 (23.53)
26-30	739 (7.57)	178 (24.09)	31 (4.19)	101 (13.67)	59 (7.98)	66 (8.93)	146 (19.76)	90 (12.18)	180 (24.36)	146 (19.76)
31-35	2470 (25.29)	531 (21.5)	113 (4.57)	416 (16.84)	167 (6.76)	205 (8.3)	430 (17.41)	347 (14.05)	651 (26.36)	469 (18.99)
36-40	1799 (18.42)	379 (21.07)	96 (5.34)	252 (14.01)	113 (6.28)	131 (7.28)	255 (14.17)	230 (12.78)	425 (23.62)	327 (18.18)
41-45	1526 (15.63)	280 (18.35)	63 (4.13)	212 (13.89)	86 (5.64)	105 (6.88)	246 (16.12)	192 (12.58)	385 (25.23)	279 (18.28)
46-50	1188 (12.17)	229 (19.28)	50 (4.21)	144 (12.12)	57 (4.8)	91 (7.66)	176 (14.81)	145 (12.21)	291 (24.49)	245 (20.62)
51-55	931 (9.53)	144 (15.47)	32 (3.44)	103 (11.06)	50 (5.37)	72 (7.73)	137 (14.72)	127 (13.64)	293 (31.47)	162 (17.4)
56-60	629 (6.44)	114 (18.12)	20 (3.18)	63 (10.02)	47 (7.47)	44 (7)	76 (12.08)	76 (12.08)	211 (33.55)	107 (17.01)
61-65	323 (3.31)	57 (17.65)	6 (1.86)	35 (10.84)	16 (4.95)	23 (7.12)	52 (16.1)	34 (10.53)	95 (29.41)	56 (17.34)
65-72	14 (0.14)	1 (7.14)	0 (0)	1 (7.14)	2 (14.29)	0 (0)	4 (28.57)	4 (28.57)	3 (21.43)	5 (35.71)

The average age of HPV-positive women was 41.31 years (±9.48); 25.29% of them were in the 31–35 years age group. In almost all age groups, HPV-16 was the most frequent type, except for the 21–25 and the 65–72 years age groups, where HPV-52 was the most common. With respect to pooled detection, P2 (56,59, 66) was the most predominant group among women between 16 and 65 years of age, while P3 (35,39, 68) was the most prevalent in the 65–72 age group (Table 1).

Multiple HPV Infections

In total, 20.29% of HPV-positive women had HPV co-infections. Patients with higher number of coinfections included one woman positive for HPV 16,18,31, 45, 52 and P2, and another woman positive for HPV 16, 31, 45 and P1, P2 and P3. In addition, one woman was positive for HPV 16, 31, 45, 51, 52 and P1, P2 and P3 (Table 2). Among patients who presented two different types of HPV, P2 and P3 was the most frequent co-occurrence (8.15%), followed by P2 and 52 (7.49%), and P2 and 16 (6.77%) (Figure 3).

Table 2.

Distribution of Women With HPV According to the Number of the Detected HPV Type.

Number of HPV Types	N	% From all (N = 68714)	% From HPV Positive (N = 9765)
1	7784	11.33	79.71
2	1522	2.21	15.59
3	353	0.51	3.61
4	92	0.13	0.94
5	11	0.02	0.11
6	2	0.00	0.02
7	1	0.00	0.01

Figure 3.

Frequency of concurrent HPV types. The figure shows the combinations for two types of HPV and the percentage of women that tested positive for each combination. The percentages are estimated from de total of patients with two types of HPV (N = 1522).

Discussion

Since HPV is still one of the most prevalent sexually transmitted infections and the cause of some types of cancer, especially cervical cancer, unceasing surveillance is an essential step for early detection and control. We present in this study the largest cohort of Peruvian women screened for HPV by molecular testing. Here, we estimated the prevalence of high-risk HPV in women who come to the AUNA network for health care in Peru.

In 2021, the Peruvian Ministry of Health (MINSA) inaugurated the first molecular laboratory for HPV detection.²⁰ Since then, molecular screening has been made available in 14 regions of Peru (out of 24), including Lima (Lima and Callao), Junín, Loreto, Arequipa, Ayacucho, Cajamarca, La Libertad, Lambayeque, Cusco, Piura, Ica, Tacna, San Martín and Ancash.²¹ According to MINSA, in 2022 alone, more than 600,000 25-64-year-old women were tested.²² However, HPV prevalence has not been reported yet.

We found a prevalence of HPV of 14.21%, which is similar to the prevalence reported in women with normal cytology in Brazil; lower than Argentina, Colombia, Ecuador, Paraguay, and Uruguay; and higher than Bolivia, Chile, Mexico and Venezuela.²³ However, it is significantly lower when compared to the prevalence including all types of cytology results (Table 3). Furthermore, the prevalence in our study is similar to the results of a meta-analysis of Peruvian women living in urban areas [11% (IC 95%: 6%–18%)].²⁴ Besides, Valderrama et al found a prevalence of 8.4% in university students from Lima, who showed up for HPV screening,¹⁵ while Santos et al. reported a prevalence of 17.7% in women without cervical cancer.²⁵ However, the prevalence of HPV in Peru varies widely depending on the study population. Considering reports that included women who underwent HPV testing for screening or for diagnosis confirmation, as well as women living in urban or rural areas, a prevalence of 33% (IC 95%: 22%–45%) has been estimated, but the heterogeneity between studies is high (98.95%).²⁴

Table 3.

Comparison of HPV Prevalence in Our Study Population Vs Prevalence Reported in Other LATAM Countries.

Study	Country	Population Study	Prevalence % (95% CI)
Present	Peru	68,714	14.21 (13.95-14.47)
Colpani V et al.^37,a	Brazil	50,822	25.1 (22.71−28.32)
Jorda GB et al.³⁸	Argentina	505	30.7 (Not available)
Patzi-churqui M et al.³⁹	Bolivia	376	27.0 (Not available)
Balanda M et al.⁴⁰	Chile	1738	11.1 (Not available)
Puerto D et al.⁴¹	Colombia	1782	60.2 (Not available)
Roman C et al.⁴²	Ecuador	120	65.0 (Not available)
Bobadilla ML et al.⁴³	Paraguay	208	54.8 (Not available)
Saldaña-Rodríguez P et al.⁴⁴	Mexico	373	69.97 (Not available)
Berois N et al.⁴⁵	Uruguay	965	20.8 (18.4-23.5)
Toro de Mendez M et al.⁴⁶	Venezuela	3651	28.5 (Not available)

^aMeta-analysis.

Remarkably, a higher prevalence was observed in Piura, focused on HPV-51, HPV-52 and the three types of pooled-HPV strains. In contrast, in other regions, HPV-16 and HPV-31 were the most frequent types. In Peru, it is well known that the existence of geographical, cultural, infrastructural and socioeconomic barriers affects the screening and evolution of some health conditions, including HPV infections. Taking into consideration that our study population belongs mostly to socioeconomic levels A and B (according with the Asociación Peruana de Empresas de Inteligencia de Mercados classification²⁶ and that these groups of patients have access to HPV-vaccination and well-implemented health facilities,²⁷ cultural and personal barriers may explain the increased prevalence in Piura. For instance, Requena et al have reported that 100% of women with abnormal cytology cared for at a public hospital in Piura were not vaccinated. Moreover, 93.3% did not have a previous history of molecular HPV screening, 55.0% had only one or two previous Pap smear controls, and the median age for starting Pap smears was 42.97 years (±12.18).²⁸ Fear and shame to undergo gynecological examinations, forgetting to schedule an appointment, and laziness have been identified as associated factors for not adhering to Pap smear controls.²⁹

Regarding the prevalence by HPV type, HPV-16 and HPV-52 were the most prevalent types, consistent with global data, where 3.2% and 0.9% of women with normal cytology were positive for HPV-16 and HPV-52, respectively. Conversely, HPV-18 was the least frequent in our study.¹⁴ In Peru, a report published in 2023, found that the most prevalent subtypes in women with normal cytology were HPV-16 (5%), HPV-31 (2.6%) and HPV-58 (1.9%), while HPV-16, HPV-52 and HPV-31 were the most prevalent in women with low-grade lesions. In high-grade lesions, HPV-16 and HPV-33 were the most frequent types, whereas in cervical cancer, HPV-16 and HPV-18 were predominant.³⁰ However, the number of studies included in this analysis was small and the studies themselves were published between 2001 to 2014.

Among the group of HPV-positive women, HPV-16, HPV-52 and HPV-P2 (56,59), were the most frequent types in all age groups, except for women between 65 and 72 years, where HPV-52 and HPV-P3 (HPV-35,39,68) were the most common. Most positive women (71.51%) were between 31 and 50 years old, with the majority clustered in the group of 31-35 years. Similarly, a notable increase in HPV prevalence among women aged 14-19 years, followed by another peak in those aged 30-34 years has been reported.³¹ In women with abnormal cytological findings, the prevalence of high-risk HPV was statistically higher in women aged between 35 and 45 years with lower levels of education, multiple pregnancies and childbirths, history of gynecological conditions and those in the premenopausal stage.³²

In our study, around 3% of women presented multiple HPV infections, the majority of which had two types of HPV. This is consistent with previous studies.^31,33,34 Although we could not assess associations with age or cytology results, previous studies have shown that multiple HPV infections were more frequent in women between 14 and 25 years and that the prevalence decreased with age. In addition, women with cervical abnormalities showed an increased prevalence of multiple HPV strains, compared to those with normal cytology.^31,35 Furthermore, multiple HPV positivity is associated with high viral loads (>3 log HPV copies/10⁵ cell) and with infection persistence.³⁶

Our study has some limitations. First, the evaluated population might not represent the general Peruvian population, since only women coming to one private health care network were included and most of them are of socioeconomic levels A and B. In addition, it was not possible to estimate the prevalence by age and cytology results, and for some HPV types, only pooled estimates were feasible. Furthermore, important sociodemographic factors that could be associated with such HPV prevalence could not be evaluated given the retrospective nature of this study and because it is not available in the analyzed dataset. Despite this, we have evaluated a large cohort of women from different regions in Peru and found that the prevalence of HPV in women coming for molecular HPV testing at Auna is similar to previous reports, highlighting the need for better strategies for prevention.

Conclusion

HPV prevalence was higher in Piura and the most prevalent types were HPV-16, HPV-52 and HPV-P2 (HPV-56, -59, −66). Arequipa had the lowest HPV prevalence, and there, the HPV-16 type was most prevalent. HPV infection was more frequent among women in the 31-15 years age group. Regarding co-occurrences, HPV-P2 (HPV-56, -59, −66) and HPV-P3 (HPV-35, -39, −68) was the most frequent one in women who presented two different types of HPV.

Our results provide relevant information regarding HPV prevalence according to geographic location and HPV type in Peru and call for improved strategies for HPV prevention and screening.

Footnotes

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Auna Ideas and Auna Laboratorio.

Ethical Statement

ORCID iD

Jhajaira M. Araujo

References

Human papillomavirus and cancer. Available from: https://www.who.int/news-room/fact-sheets/detail/human-papilloma-virus-and-cancer

Merchant

. Infectious disease. Update on emerging infections: news from the centers for disease control and prevention. Ann Emerg Med. 2011;58:67-68.

GYF

Bierman

Beardsley

Chang

Burk

. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423-428.

Della Fera

Warburton

Coursey

Khurana

McBride

. Persistent human papillomavirus infection. Viruses. 2021;13:13.

Alhamlan

Alfageeh

Al Mushait

Al-Badawi

Al-Ahdal

. Human papillomavirus-associated cancers. Adv Exp Med Biol. 2021;1313:1-14.

Serrano

Brotons

Bosch

Bruni

. Epidemiology and burden of HPV-related disease. Best Pract Res Clin Obstet Gynaecol. 2018;47:14-26.

Formana

de Martel

Lacey

, et al. Global burden of human papillomavirus and related diseases. Vaccine. Vaccine. 2012;30(Suppl 5):F12-F23.

de Martel

Plummer

Vignat

Franceschi

. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141:664-670.

Bray

Laversanne

Sung

, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.

10.

Walboomers

JMM

Jacobs

Manos

, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.

11.

Bortolli

APR

Treco

Vieira

, et al. Prevalence of HPV and associated factors in a population of women living in southern Brazil. Braz J Microbiol. 2022;53:1979-1986.

12.

Franceschi

Herrero

Clifford

, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer. 2006;119:2677-2684.

13.

Kombe Kombe

Zahid

, et al. Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. Front Public Health. 2020;8:552028.

14.

Bruni

Diaz

Castellsagué

Ferrer

Bosch

De Sanjosé

. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202:1789-1799.

15.

Valderrama

Campos

Cárcamo

García

. Factores asociados a lesiones cervicales o presencia del virus del papiloma humano en dos poblaciones de estudiantes de Lima. Rev Peru Med Exp Salud Pública. 2007;24:234-239.

16.

Almonte

Ferreccio

Gonzales

, et al. Risk factors for high-risk human papillomavirus infection and cofactors for high-grade cervical disease in Peru. Int J Gynecol Cancer. 2011;21:1654-1663.

17.

Iwasaki

Galvez-Philpott

Arias-Stella

. Prevalence of high-risk human papillomavirus by cobas 4800 HPV test in urban Peru. Braz J Infect Dis. 2014;18:469-472.

18.

Martorell

Garcia-Garcia

Gomez-Cabrero

Del Aguila

. Comparison of the prevalence and distribution of human papillomavirus infection and cervical lesions between urban and native habitants of an Amazonian region of Peru. Genet Mol Res. 2012;11:2099-2106.

19.

Von Elm

Altman

Egger

Pocock

Gøtzsche

Vandenbroucke

STROBE Initiative . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573-577. Available from: https://pubmed.ncbi.nlm.nih.gov/17938396/

20.

Ministry of Health . Minsa implementa prueba molecular para diagnóstico del cáncer de cuello uterino - Noticias - Ministerio de Salud - Plataforma del Estado Peruano 2021. Available from: https://www.gob.pe/institucion/minsa/noticias/494734-minsa-implementa-prueba-molecular-para-diagnostico-del-cancer-de-cuello-uterino

21.

Ministry of Health . Listado de establecimientos de salud que realizan pruebas moleculares para la detección del Virus del Papiloma Humano (VPH) - Informes y publicaciones - Ministerio de Salud - Plataforma del Estado Peruano 2023. Available from: https://www.gob.pe/institucion/minsa/informes-publicaciones/4028155

22.

Ministry of Health . Minsa prevé implementar la detección molecular del VPH en 12 regiones del país - Noticias - Ministerio de Salud - Plataforma del Estado Peruano 2023. Available from: https://www.gob.pe/institucion/minsa/noticias/734333-minsa-preve-implementar-la-deteccion-molecular-del-vph-en-12-regiones-del-pais

23.

Bruni

Albero

Serrano

, et al. Human papillomavirus and related diseases in the world. Summary report 10 march 2023. Available from: https://hpvcentre.net/statistics/reports/XWX.pdf?t=1721678154859

24.

Leon Aea

Figueroa Machaca

. Revisión sistemática y metaanálisis de la prevalencia del Virus Papiloma Humano en población general femenina peruana, con citología ó histología cervical normal. lesiones premalignas y neoplasia de cérvix. Available from: https://hdl.handle.net/10757/667635

25.

Santos

Muñoz

Klug

, et al. HPV types and cofactors causing cervical cancer in Peru. Br J Cancer. 2001;85:966-971.

26.

Acuña Sillo

. Cuaderno de investigación de mercados: teoría y práctica. Un enfoque aplicado. Universidad de Lima. Available from: https://repositorio.ulima.edu.pe/handle/20.500.12724/5626

27.

Aguilar

Pinto

Araujo

, et al. Control of cervical cancer in Peru: current barriers and challenges for the future. Mol Clin Oncol. 2016;5:241-245.

28.

Requena Castillo

. Historial de tamizaje citológico cervical en pacientes con resultados intraepiteliales anómalos por papanicolaou en el Hospital III José Cayetano Heredia de julio a diciembre 2018. Piura: Universidad Nacional de Piura; 2019 Available from: https://repositorio.unp.edu.pe/handle/UNP/1643

29.

Medrano Santa Cruz

. Factores socioculturales y psicológicos que influyen en la decisión de las usuarias para la toma de papanicolaou. Centro de Salud Carlos Cueto Fernandini – 2014. Available from: https://cybertesis.unmsm.edu.pe/handle/20.500.12672/4055

30.

Bruni

Albero

Serrano

, et al. Human papillomavirus and related diseases report Peru 2023. Available from: https://www.hpvcentre.net/

31.

Argyri

Papaspyridakos

Tsimplaki

, et al. A cross sectional study of HPV type prevalence according to age and cytology. BMC Infect Dis. 2013;13:53-58.

32.

Song

Lyu

Ding

, et al. Prevalence and genotype distribution of high-risk human papillomavirus infection in women with abnormal cervical cytology: a population-based study in shanxi province, China. Cancer Manag Res. 2020;12:12583-12591.

33.

Wentzensen

Schiffman

Dunn

, et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer. 2009;125:2151-2158.

34.

Wang

Han

. The correlation between multiple HPV infections and the occurrence, development, and prognosis of cervical cancer. In: Front Microbiol. Lausanne: Frontiers Media SA; 2023:14.

35.

Luo

Zeng

Luo

, et al. Epidemiologic characteristics of high-risk HPV and the correlation between multiple infections and cervical lesions. BMC Infect Dis. 2023;23:667.

36.

Oyervides-Muñoz

Pérez-Maya

Sánchez-Domínguez

, et al. Multiple HPV infections and viral load association in persistent cervical lesions in Mexican women. Viruses. 2020;12:380.

37.

Colpani

Falcetta

Bidinotto

, et al. Prevalence of human papillomavirus (HPV) in Brazil: a systematic review and meta-analysis. PLoS One. 2020;15:380.

38.

Jordá

Ramos

Mosmann

Lopez

Wegert

Cuffini

. [Prevalence of human papillomavirus and associated risk factors in women affiliated with state health insurance in Posadas, Misiones (Argentina)]. Rev Chilena Infectol. 2020;37:111-116.

39.

Patzi-Churqui

Terrazas-Aranda

Liljeqvist

JÅ

Lindh

Eriksson

. Prevalence of viral sexually transmitted infections and HPV high-risk genotypes in women in rural communities in the Department of La Paz, Bolivia. BMC Infect Dis. 2020;20:204.

40.

Balanda

Quiero

Vergara

, et al. Prevalence of human papillomavirus infection among women presenting for cervical cancer screening in Chile, 2014-2015. Med Microbiol Immunol. 2016;205:585-594.

41.

Puerto

Wiesner

Lozano

, et al. Prevalencia de infecciones por VPH en un grupo de mujeres colombianas no vacunadas de 18-25 años: una medida de referencia para el monitoreo de la vacuna. Revista Colombiana de Cancerología. 2016;21:57-58.

42.

Roman

Andrade

Hernández

, et al. Biological, demographic, and health factors associated with HPV infection in Ecuadorian women. Front Public Health. Front Public Health. 2023;11:1158270.

43.

Bobadilla

Villagra

Violeta

Deluca

De Paula

. High prevalence and co-infection of high-risk Human Papillomavirus genotypes among unvaccinated young women from Paraguay. PLoS One. PLoS One. 2023;18:e0283542.

44.

Saldaña-Rodríguez

Bahena-Román

Delgado-Romero

Madrid-Marina

Torres-Poveda

. Prevalence and risk factors for high-risk human papillomavirus infection and cervical disorders: baseline findings from an human papillomavirus cohort study. Cancer Control. 2023;30:10732748231202925.

45.

Berois

Heard

Fort

, et al. Prevalence of type-specific HPV infection in Uruguay. J Med Virol. 2014;86:647-652.

46.

Toro de Méndez

López de Sánchez

. Infección por virus papiloma humano en pacientes con citología de cuello uterino negativa. Rev Obstet Ginecol Venez. Sociedad de obstetricia y ginecología de Venezuela. 2017;77:11-20.

Prevalence OF HPV IN a Peruvian Healthcare Network: A Descriptive Cross-Sectional Study

Abstract

Introduction

Methods

Results

Conclusion

Keywords

Background

Methods

Study Design and Population

HPV Testing

Statistical Analysis

Ethical Considerations

Results

HPV Prevalence

HPV Type Distribution in HPV- Positive Women

Multiple HPV Infections

Discussion

Conclusion

Footnotes

Declaration of conflicting interests

Funding

Ethical Statement

ORCID iD

References